Analytical methods
Bidirectional sequencing of coding regions.
Analytical validation
Direct sequencing of both strands, verification of sequence results with genomic DNA from the second blood sample. External validation through exchange of DNA control samples with other diagnostic institutions.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) 1 per 30 000.
1. 9 If applicable, prevalence in the ethnic group of investigated person Not available.
Diagnostic setting
Comment: Pre-implantation/prenatal diagnostics is rarely done because adequate prevention/therapy of the associated diseases is available. Theoretically, we would recommend pre-implantation diagnosis in MEN 2B families, but these cases are very rare. FMTC: frequency of MTC 80%, rarely pheochromocytoma/parathyroid disease (below 5%). [6] [7] [8] 2.6 Negative clinical predictive value (probability of not developing the disease if the test is negative) Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
TEST CHARACTERISTICS
Index case in that family had been tested: About 98%. Index case in that family had not been tested: Depending on age, phenotype and number of family members under investigation.
CLINICAL UTILITY
In MEN 2, DNA analysis has obtained a central role in diagnosis and management. For this reason it is inconceivable that in MEN 2 families patients may refuse early DNA analysis for their children at risk. Delay in treatment may have serious consequences for survival and quality of life.
3.1 (Differential) diagnosis: The tested person is clinically affected (To be answered if in 1.10 'A' was marked) If a person is clinically affected with MTC, about 70-75% of cases are sporadic, the remaining 25-30% belong to the hereditary variety (MEN 2/FMTC). In all cases of MTC genetic testing for mutations in the RET proto-oncogene is recommended. 1 The probability that an individual with apparent sporadic MTC will be found to have a RET mutation is 1-7%. 1, 9, 10 In rare families, both HSCR and MEN 2 appear to segregate with germline RET mutations in codon 609, 611, 618, or 620. 11, 12 3.1.1 Can a diagnosis be made other than through a genetic test? 3.1.2 Describe the burden of alternative diagnostic methods to the patient? In the past, pentagastrin and calcium infusion tests were used to stimulate calcitonin secretion by thyroid C-cells, but nowadays RET-mutation screening is available for familial MTC and thus these tests have lost their clinical significance with respect to diagnosis. The widespread availability of RET gene mutation analysis and prophylactic thyroidectomy in MEN 2 disease-gene carriers has made periodical C-cell stimulation tests largely obsolete for detection of MTC in MEN 2 families.
For detection of MTC, C-cell stimulation tests are useful for family members who refuse DNA analysis. In addition, preoperatively it may facilitate a decision with regard to the extensiveness of the surgical procedure.
Occasionally, MTCs do not secrete calcitonin, 13,14 but this has not been observed in MEN 2 gene carriers.
Tests for pheochromocytoma and HPT significantly add to the burden.
How is the cost effectiveness of alternative diagnostic methods to be judged?
After 3-4 appointments with calcitonin stimulation test the costs are equal to the molecular diagnostic test. Savings through unnecessary testing for pheochromocytoma and HPT further increase the cost effectiveness.
Will disease management be influenced by the result of a genetic test?
3.2 Predictive setting: The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked)
Will the result of a genetic test influence lifestyle and prevention? If the test result is positive (please describe):
Positive test result: Depending on the detected mutation the patient should undergo prophylactic thyroidectomy or yearly calcitonin measurement. Likewise, also depending on the detected mutation the patient should undergo biochemical testing for pheochromocytoma and HPT. If the test result is negative (please describe):
Negative test result: Person can be excluded from further evaluations. MTC can be cured or prevented by early thyroidectomy. 1,6 Also pheochromocytoma will be detected and removed earlier.
Prognosis (please describe)
Early diagnosis and pre-emptive thyroidectomy allows cure from MTC. 6 Type of mutation predicts risk of pheochromocytoma and adenoma of parathyroid glands. 15 These problems require lifelong attention. Management (please describe) Molecular diagnosis before age 4 allows therapy depending on the mutated codon in the RET proto-oncogene. In MEN 2B molecular diagnosis should be done as soon as possible within the first year of life. 1 
Which options in view of

Prenatal diagnosis (To be answered if in 2.10 'D' was marked)
This is rarely necessary, because the disease can be managed properly (prophylactic thyroidectomy at an adequate age determined by the respective RET mutation, adrenalectomy in pre-symptomatic stage of pheochromocytoma, parathyroidectomy in asymptomatic stage of hyperparathyroidism).
3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnostic? Yes, but this is rarely done, because postnatal therapy is available.
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) Molecular diagnosis of the proband allows for a precise recommendation of further therapy (prophylactic thyroidectomy at the appropriate age, depending on the respective RET mutation) and also for recommendation concerning the commencement and frequency of biochemical testing for pheochromocytoma and hyperparathyroidism. Cure of MTC is only possible as long as MTC is limited to the thyroid gland; therefore diagnosis at an early stage is the prerequisite for cure. Genetic test allows for regular biochemical screening using epinephrine and nor-epinephrine analysis to prevent hypertensive crisis induced by pheochromocytoma, 16 and regular serum calcium and parathyroid hormone measurement to diagnose hyperparathyroidism at an early stage. 15 Molecular diagnosis of the proband allows for an accurate and faster diagnosis in first-degree relatives.
